In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci.

Antimicrobial Agents and Chemotherapy
C C SandersR V Goering

Abstract

In vitro tests were performed with Sch 21420 and Sch 22591 to determine (i) their activity in comparison to six other aminoglycosides against 343 clinical isolates, and (ii) whether synergy with penicillin G could be demonstrated with enterococci. In broth dilution tests, Sch 22591 was more active than the seven other aminoglycosides against Staphylococcus aureus, Enterobacteriaceae, and most nonfermenting gram-negative bacilli. Sch 22591 was as active as tobramycin against Pseudomonas aeruginosa. The activity of Sch 21420 was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae. Sch 21420, amikacin, and kanamycin were (i) more active than the other five aminoglycosides against Proteus rettgeri and Providencia stuartii, but (ii) less active than the other five aminoglycosides against Neisseria gonorrhoeae, enterococci, most nonfermenting gram-negative bacilli, Proteus mirabilis, and Proteus morganii. Studies on the bactericidal activity of Sch 22591 with penicillin indicated a synergistic interaction against enterococci, including strains highly resistant to streptomycin and kanamycin. This could be demonstrated with combin...Continue Reading

References

Jan 1, 1978·Antimicrobial Agents and Chemotherapy·J A WaitzP J Chiu
Nov 1, 1976·Antimicrobial Agents and Chemotherapy·G H MillerJ A Waitz
Feb 1, 1974·Antimicrobial Agents and Chemotherapy·K E PriceM D DeFuria
Dec 1, 1974·The Journal of Antibiotics·R T TestaM J Weinstein
Jun 1, 1963·Journal of Bacteriology·D S KELLOGGD I PIRKLE

❮ Previous
Next ❯

Citations

Oct 1, 1979·Antimicrobial Agents and Chemotherapy·L I RankinL L Isaacs
Oct 1, 1980·Antimicrobial Agents and Chemotherapy·A L BarryE H Gerlach
Aug 1, 1981·Antimicrobial Agents and Chemotherapy·C C Sanders, W E Sanders
Apr 1, 1987·Genitourinary Medicine·J Söltz-SzötsC Poitschek
Jul 1, 1990·Urology·B A Cunha
Jun 30, 1986·The American Journal of Medicine·W E SiegenthalerR Luthy
Aug 1, 1995·Journal of Chemotherapy·G Gialdroni Grassi
Jun 1, 1984·Infection Control : IC·R J Geller, S M Norris
Apr 2, 1999·Clinical Orthopaedics and Related Research·J T MaderJ Calhoun
Mar 1, 1996·Antimicrobial Agents and Chemotherapy·Y YoshiyamaD Beauchamp

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.